Type 2 diabetes-related genetic risk scores associated with variations in fasting plasma glucose and development of impaired glucose homeostasis in the prospective DESIR study
- PMID: 24893864
- DOI: 10.1007/s00125-014-3277-x
Type 2 diabetes-related genetic risk scores associated with variations in fasting plasma glucose and development of impaired glucose homeostasis in the prospective DESIR study
Abstract
Aims/hypothesis: Genome-wide association studies have firmly established 65 independent European-derived loci associated with type 2 diabetes and 36 loci contributing to variations in fasting plasma glucose (FPG). Using individual data from the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study, we evaluated the contribution of three genetic risk scores (GRS) to variations in metabolic traits, and to the incidence and prevalence of impaired fasting glycaemia (IFG) and type 2 diabetes.
Methods: Three GRS (GRS-1, 65 type 2 diabetes-associated single nucleotide polymorphisms [SNPs]; GRS-2, GRS-1 combined with 24 FPG-raising SNPs; and GRS-3, FPG-raising SNPs alone) were analysed in 4,075 DESIR study participants. GRS-mediated effects on longitudinal variations in quantitative traits were assessed in 3,927 nondiabetic individuals using multivariate linear mixed models, and on the incidence and prevalence of hyperglycaemia at 9 years using Cox and logistic regression models. The contribution of each GRS to risk prediction was evaluated using the C-statistic and net reclassification improvement (NRI) analysis.
Results: The two most inclusive GRS were significantly associated with increased FPG (β = 0.0011 mmol/l per year per risk allele, p GRS-1 = 8.2 × 10(-5) and p GRS-2 = 6.0 × 10(-6)), increased incidence of IFG and type 2 diabetes (per allele: HR GRS-1 1.03, p = 4.3 × 10(-9) and HR GRS-2 1.04, p = 1.0 × 10(-16)), and the 9 year prevalence (OR GRS-1 1.13 [95% CI 1.10, 1.17], p = 1.9 × 10(-14) for type 2 diabetes only; OR GRS-2 1.07 [95% CI 1.05, 1.08], p = 7.8 × 10(-25), for IFG and type 2 diabetes). No significant interaction was found between GRS-1 or GRS-2 and potential confounding factors. Each GRS yielded a modest, but significant, improvement in overall reclassification rates (NRI GRS-1 17.3%, p = 6.6 × 10(-7); NRI GRS-2 17.6%, p = 4.2 × 10(-7); NRI GRS-3 13.1%, p = 1.7 × 10(-4)).
Conclusions/interpretation: Polygenic scores based on combined genetic information from type 2 diabetes risk and FPG variation contribute to discriminating middle-aged individuals at risk of developing type 2 diabetes in a general population.
Similar articles
-
The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population.Diabetes. 2008 Aug;57(8):2253-7. doi: 10.2337/db07-1807. Epub 2008 Jun 12. Diabetes. 2008. PMID: 18556336 Free PMC article.
-
Combined effects of 17 common genetic variants on type 2 diabetes risk in a Han Chinese population.Diabetologia. 2010 Oct;53(10):2163-6. doi: 10.1007/s00125-010-1826-5. Epub 2010 Jun 17. Diabetologia. 2010. PMID: 20556352
-
Assessing the clinical utility of a genetic risk score constructed using 49 susceptibility alleles for type 2 diabetes in a Japanese population.J Clin Endocrinol Metab. 2013 Oct;98(10):E1667-73. doi: 10.1210/jc.2013-1642. Epub 2013 Aug 16. J Clin Endocrinol Metab. 2013. PMID: 23956346
-
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD012661. doi: 10.1002/14651858.CD012661.pub2. Cochrane Database Syst Rev. 2018. PMID: 30371961 Free PMC article.
-
Meta-analysis investigating associations between healthy diet and fasting glucose and insulin levels and modification by loci associated with glucose homeostasis in data from 15 cohorts.Am J Epidemiol. 2013 Jan 15;177(2):103-15. doi: 10.1093/aje/kws297. Epub 2012 Dec 19. Am J Epidemiol. 2013. PMID: 23255780 Free PMC article. Review.
Cited by
-
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.Diabetologia. 2015 Sep;58(9):2051-5. doi: 10.1007/s00125-015-3659-8. Epub 2015 Jun 7. Diabetologia. 2015. PMID: 26049403
-
Genetic risk scores in the prediction of plasma glucose, impaired insulin secretion, insulin resistance and incident type 2 diabetes in the METSIM study.Diabetologia. 2017 Sep;60(9):1722-1730. doi: 10.1007/s00125-017-4313-4. Epub 2017 Jun 1. Diabetologia. 2017. PMID: 28573393
-
Mediterranean Diet Adherence and Genetic Background Roles within a Web-Based Nutritional Intervention: The Food4Me Study.Nutrients. 2017 Oct 11;9(10):1107. doi: 10.3390/nu9101107. Nutrients. 2017. PMID: 29019927 Free PMC article. Clinical Trial.
-
Genomic risk score provides predictive performance for type 2 diabetes in the UK biobank.Acta Diabetol. 2021 Apr;58(4):467-474. doi: 10.1007/s00592-020-01650-1. Epub 2021 Jan 3. Acta Diabetol. 2021. PMID: 33392712
-
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.Endocr Rev. 2015 Dec;36(6):E1-E150. doi: 10.1210/er.2015-1010. Epub 2015 Nov 6. Endocr Rev. 2015. PMID: 26544531 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical